Alzheimer's Disease Clinical Trials in Philadelphia

Showing 81-100 of 127 trials

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT03088956

The objectives of the study are to; (1) estimate the change in disease -related cognitive decline over 1 year on a battery of cognitive tests administered to participants with early-stage symptomatic Behavioral Variant Frontotemporal Dementia (bvFTD) phenotypic variant; (2) identify the cognitive test or brief battery of cognitive tests which are the most sensitive to detect bvFTD progression; (3) determine the optimal schedule of administration of cognitive tests to detect bvFTD progression; (4) evaluate the relationship between cognitive tests and measures of behavior, function, caregiver's burden, quality of life (QOL); and (5) obtain blood samples for genetic and exploratory biomarkers correlations.

Frontotemporal DementiaBehavioral Variant Frontotemporal Dementia

Biogen47 participantsStarted Jan 2018

Birmingham, Alabama, United States • Los Angeles, California, United States • Boca Raton, Florida, United States +9 more locations

TERMINATEDPHASE3< 1 mile

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

NCT01127633

This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).

Alzheimer's Disease

Eli Lilly and Company1,457 participantsStarted Dec 2010

Phoenix, Arizona, United States • Sun City, Arizona, United States • Tucson, Arizona, United States +144 more locations

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Alzheimer's Disease Trials in Other Cities

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Hand Grasping Techniques on Eliciting the Grasp Reflex in Patients With Dementia

Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Partners in Dementia Care: A Telephone Care Consultation Intervention Provided to Veterans in Partnership With Local Alzheimer's Association Chapters

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease

Other Conditions in Philadelphia